The Global Patent Exchange

Web: |  Phone: (650)292-4849 |  Email:

Technology Wanted

Seeking New Technology in the Area of Thrombosis

We are a large pharmaceutical company proactively seeking new partnership opportunities.


As a fortune 500 multinational corporation operating in the healthcare sector, we are looking for certain new technologies to license or acquire. If you have technologies in these areas, we welcome you to get in touch via Tynax. We have the sales channels to effectively bring new healthcare products to market.

We are keenly aware of and continuously review discoveries and developments across the entire drug discovery and development community. To achieve this, our Review and Licensing Committees, each target a specific therapeutic area or technology. This means that we provide a formal review and response for every viable opportunity.

Area of Interest: Thrombosis

- Novel antithrombotic agent in late-stage (Phase III) clinical development

> Factor Xa inhibitor; direct thrombin inhibitor; other mechanism (novel mechanism with inherent reduced bleeding risk)

> Oral, once daily preferred

- Novel antiplatelet againe in late-stage (Phase III) development

> Overcomes the limitation of clopidogrel (rapid onset, limited "resistance," possibily reversible)

> Must be oral and preferably have one additional route of administration


- Novel technology to assist in bridge along continuum of PK, magnitude of <i>ex vivo</i> effect, reduction in events/risk

- Point-of-care clinical tests only as needed to assess therapeutic effect of novel agent - to identify responder population or to guide clinicians on difficult to manage patients

Not Interested in:

- IV-only antithrombotic or antiplatelet agents

- Thrombolytics

- Point-of-care clinical tests, unless as necessary to support clinical development of a novel agent

Patents and Intellectual Property

We will only consider technology covered by a patent.

View this listing on the Tynax website: